BACKGROUND Unraveling the pathogenesis of colorectal cancer(CRC)can aid in developing prevention and treatment strategies.Aurora kinase A(AURKA)is a key participant in mitotic control and interacts with its co-activat...BACKGROUND Unraveling the pathogenesis of colorectal cancer(CRC)can aid in developing prevention and treatment strategies.Aurora kinase A(AURKA)is a key participant in mitotic control and interacts with its co-activator,the targeting protein for Xklp2(TPX2)microtubule nucleation factor.AURKA is associated with poor clinical outcomes and high risks of CRC recurrence.AURKA/TPX2 co-overexpression in cancer may contribute to tumorigenesis.Despite its pivotal role in CRC development and progression,the action mechanism of AURKA remains unclear.Further research is needed to explore the complex interplay between AURKA and TPX2 and to develop effective targeted treatments for patients with CRC.AIM To compare effects of AURKA and TPX2 and their combined knockdown on CRC cells.METHODS We evaluated three CRC gene datasets about CRC(GSE32323,GSE25071,and GSE21510).Potential hub genes associated with CRC onset were identified using the Venn,search tool for the retrieval of interacting genes,and KOBAS platforms,with AURKA and TPX2 emerging as significant factors.Subsequently,cell models with knockdown of AURKA,TPX2,or both were constructed using SW480 and LOVO cells.Quantitative real-time polymerase chain reaction,western blotting,cell counting kit-8,cell cloning assays,flow cytometry,and Transwell assays were used.RESULTS Forty-three highly expressed genes and 39 poorly expressed genes overlapped in cancer tissues compared to controls from three datasets.In the protein-protein interaction network of highly expressed genes,AURKA was one of key genes.Its combined score with TPX2 was 0.999,and their co-expression score was 0.846.In CRC cells,knockdown of AURKA,TPX2,or both reduced cell viability and colony number,while blocking G0/G1 phase and enhancing cell apoptosis.Additionally,they were weakened cell proliferation and migration abilities.Furthermore,the expression levels of B-cell lymphoma-2-Associated X,caspase 3,and tumor protein P53,and E-cadherin increased with a decrease in B-cell lymphoma-2,N-cadherin,and vimentin proteins.These effects were amplified when both AURKA and TPX2 were concurrently downregulated.CONCLUSION Combined knockdown of AURKA and TPX2 was effective in suppressing the malignant phenotype in CRC.Coinhibition of gene expression is a potential developmental direction for CRC treatment.展开更多
目的观察Aurora A在人前列腺癌中的表达情况,探讨Aurora A是否在前列腺癌发生发展中起一定作用。方法采用RT-PCR、免疫组织化学和Western blot,检测在前列腺癌组织及其细胞系中Aurora A mRNA和蛋白表达。同时,在前列腺癌细胞系PC3中导...目的观察Aurora A在人前列腺癌中的表达情况,探讨Aurora A是否在前列腺癌发生发展中起一定作用。方法采用RT-PCR、免疫组织化学和Western blot,检测在前列腺癌组织及其细胞系中Aurora A mRNA和蛋白表达。同时,在前列腺癌细胞系PC3中导入靶向Aurora A mRNA的DNA核酶,观察抑制Aurora A对前列腺癌细胞生长的影响。结果91%的前列腺癌组织和三种前列腺癌细胞系(PC3、LNCaP和Du145)中Aurora A表达阳性,而且,靶向Aurora A mRNA的DNA核酶导入PC3细胞后抑制了Aurora A表达,使PC3细胞停滞在G2/M期,并促进细胞凋亡。结论Aurora A可能在前列腺癌形成中起一定作用,Aurora A可望成为前列腺癌治疗中有价值的靶点。展开更多
目的:采用RNA干扰技术抑制人脑胶质瘤U251细胞中Aurora A基因的表达,研究其对U251细胞化疗敏感性的影响。方法:设计并合成特异性针对Aurora A基因的siRNA,转染至U251细胞中,采用RT-PCR和Western blot检测Aurora A mRNA和蛋白表达情况,...目的:采用RNA干扰技术抑制人脑胶质瘤U251细胞中Aurora A基因的表达,研究其对U251细胞化疗敏感性的影响。方法:设计并合成特异性针对Aurora A基因的siRNA,转染至U251细胞中,采用RT-PCR和Western blot检测Aurora A mRNA和蛋白表达情况,同时利用MTT试验和流式细胞仪检测在化疗药物尼莫司汀(ACNU)作用下转染Aurora A siRNA前后U251细胞增殖及凋亡情况的变化。结果:转染Aurora A siRNA后,U251细胞Aurora A mRNA表达受到抑制(P<0.01),蛋白表达水平降低。ACNU对转染Aurora A siRNA后U251细胞的增殖抑制作用明显增强(P<0.01),同时在ACNU作用下转染后U251细胞的凋亡率也显著增加(P<0.05)。结论:体外合成的针对Aurora A基因的特异性siRNA成功的抑制了U251细胞中Aurora A基因的表达,并能提高胶质瘤细胞的化疗敏感性。展开更多
Objective： Aurora A kinase representing a family of evolutionadly conserved mitotic serine/threonine kinases has been found elevated in human lung adenocarcinoma cell line A549. It is suggested that the overexpressio...Objective： Aurora A kinase representing a family of evolutionadly conserved mitotic serine/threonine kinases has been found elevated in human lung adenocarcinoma cell line A549. It is suggested that the overexpression of Aurora A contributes to the carcinogenesis, chromosomal instability （CIN）, and de-differentiation of lung cancers. To address its possibility as a therapeutic target for lung cancer, we employed the antisense oligodeoxynucleotide （ASODN） technique to inhibit Aurora A expression and investigate its effects on tumor growth and cell cycle of A549, as well as the chemosensitivity to paclitaxel. Methods： Aurora AASODN was synthesized and transfected into A549 cells by lipofectAMINE 2000. Aurora A mRNA and protein expression were examined by reverse transcription-polymerase chain reaction （RT-PCR） and Western blot respectively. Cell cycle distribution was observed by flow cytometer. MTT assay was used to evaluate cell inhibition ratio before and after transfection. Results： The proliferation of the A549 cells was inhibited by Aurora A ASODN dose and time dependently. It was also observed that the IC50 of A549 cells after 48 hours＇ treatment of ASODN was about 300 nmol/L and under such circumstances, the Aurora A mRNA and protein expression significantly decreased （P 〈 0.05）, along with the induction of accumulation of cells in S phase and the G2-M transition. Furthermore, cell inhibition ratio of the combination of Aurora AASODN and paclitaxel was higher significantly than paclitaxel （P 〈 0.05） or Aurora AASODN alone （P 〈 0.05）. Conclusion： Inhibition of Aurora A expression can result in the suppression of cell growth and chemosensitizing activity to paclitaxel in human lung cancer cell line A549.展开更多
文摘BACKGROUND Unraveling the pathogenesis of colorectal cancer(CRC)can aid in developing prevention and treatment strategies.Aurora kinase A(AURKA)is a key participant in mitotic control and interacts with its co-activator,the targeting protein for Xklp2(TPX2)microtubule nucleation factor.AURKA is associated with poor clinical outcomes and high risks of CRC recurrence.AURKA/TPX2 co-overexpression in cancer may contribute to tumorigenesis.Despite its pivotal role in CRC development and progression,the action mechanism of AURKA remains unclear.Further research is needed to explore the complex interplay between AURKA and TPX2 and to develop effective targeted treatments for patients with CRC.AIM To compare effects of AURKA and TPX2 and their combined knockdown on CRC cells.METHODS We evaluated three CRC gene datasets about CRC(GSE32323,GSE25071,and GSE21510).Potential hub genes associated with CRC onset were identified using the Venn,search tool for the retrieval of interacting genes,and KOBAS platforms,with AURKA and TPX2 emerging as significant factors.Subsequently,cell models with knockdown of AURKA,TPX2,or both were constructed using SW480 and LOVO cells.Quantitative real-time polymerase chain reaction,western blotting,cell counting kit-8,cell cloning assays,flow cytometry,and Transwell assays were used.RESULTS Forty-three highly expressed genes and 39 poorly expressed genes overlapped in cancer tissues compared to controls from three datasets.In the protein-protein interaction network of highly expressed genes,AURKA was one of key genes.Its combined score with TPX2 was 0.999,and their co-expression score was 0.846.In CRC cells,knockdown of AURKA,TPX2,or both reduced cell viability and colony number,while blocking G0/G1 phase and enhancing cell apoptosis.Additionally,they were weakened cell proliferation and migration abilities.Furthermore,the expression levels of B-cell lymphoma-2-Associated X,caspase 3,and tumor protein P53,and E-cadherin increased with a decrease in B-cell lymphoma-2,N-cadherin,and vimentin proteins.These effects were amplified when both AURKA and TPX2 were concurrently downregulated.CONCLUSION Combined knockdown of AURKA and TPX2 was effective in suppressing the malignant phenotype in CRC.Coinhibition of gene expression is a potential developmental direction for CRC treatment.
文摘目的观察Aurora A在人前列腺癌中的表达情况,探讨Aurora A是否在前列腺癌发生发展中起一定作用。方法采用RT-PCR、免疫组织化学和Western blot,检测在前列腺癌组织及其细胞系中Aurora A mRNA和蛋白表达。同时,在前列腺癌细胞系PC3中导入靶向Aurora A mRNA的DNA核酶,观察抑制Aurora A对前列腺癌细胞生长的影响。结果91%的前列腺癌组织和三种前列腺癌细胞系(PC3、LNCaP和Du145)中Aurora A表达阳性,而且,靶向Aurora A mRNA的DNA核酶导入PC3细胞后抑制了Aurora A表达,使PC3细胞停滞在G2/M期,并促进细胞凋亡。结论Aurora A可能在前列腺癌形成中起一定作用,Aurora A可望成为前列腺癌治疗中有价值的靶点。
文摘目的:采用RNA干扰技术抑制人脑胶质瘤U251细胞中Aurora A基因的表达,研究其对U251细胞化疗敏感性的影响。方法:设计并合成特异性针对Aurora A基因的siRNA,转染至U251细胞中,采用RT-PCR和Western blot检测Aurora A mRNA和蛋白表达情况,同时利用MTT试验和流式细胞仪检测在化疗药物尼莫司汀(ACNU)作用下转染Aurora A siRNA前后U251细胞增殖及凋亡情况的变化。结果:转染Aurora A siRNA后,U251细胞Aurora A mRNA表达受到抑制(P<0.01),蛋白表达水平降低。ACNU对转染Aurora A siRNA后U251细胞的增殖抑制作用明显增强(P<0.01),同时在ACNU作用下转染后U251细胞的凋亡率也显著增加(P<0.05)。结论:体外合成的针对Aurora A基因的特异性siRNA成功的抑制了U251细胞中Aurora A基因的表达,并能提高胶质瘤细胞的化疗敏感性。
基金Hubei Provincial Science and Technology Key Program Foundation (No. 2004AA304B08)
文摘Objective： Aurora A kinase representing a family of evolutionadly conserved mitotic serine/threonine kinases has been found elevated in human lung adenocarcinoma cell line A549. It is suggested that the overexpression of Aurora A contributes to the carcinogenesis, chromosomal instability （CIN）, and de-differentiation of lung cancers. To address its possibility as a therapeutic target for lung cancer, we employed the antisense oligodeoxynucleotide （ASODN） technique to inhibit Aurora A expression and investigate its effects on tumor growth and cell cycle of A549, as well as the chemosensitivity to paclitaxel. Methods： Aurora AASODN was synthesized and transfected into A549 cells by lipofectAMINE 2000. Aurora A mRNA and protein expression were examined by reverse transcription-polymerase chain reaction （RT-PCR） and Western blot respectively. Cell cycle distribution was observed by flow cytometer. MTT assay was used to evaluate cell inhibition ratio before and after transfection. Results： The proliferation of the A549 cells was inhibited by Aurora A ASODN dose and time dependently. It was also observed that the IC50 of A549 cells after 48 hours＇ treatment of ASODN was about 300 nmol/L and under such circumstances, the Aurora A mRNA and protein expression significantly decreased （P 〈 0.05）, along with the induction of accumulation of cells in S phase and the G2-M transition. Furthermore, cell inhibition ratio of the combination of Aurora AASODN and paclitaxel was higher significantly than paclitaxel （P 〈 0.05） or Aurora AASODN alone （P 〈 0.05）. Conclusion： Inhibition of Aurora A expression can result in the suppression of cell growth and chemosensitizing activity to paclitaxel in human lung cancer cell line A549.
